Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Dec;35(12):2649–2651. doi: 10.1128/aac.35.12.2649

Development of resistance to ciprofloxacin in nutrient-rich and nutrient-limited growth conditions in vitro by Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

M I Ferguson 1, E M Scott 1, P S Collier 1
PMCID: PMC245449  PMID: 1810202

Abstract

Five serial exposures of mucoid Pseudomonas aeruginosa from patients with cystic fibrosis to subinhibitory concentrations of ciprofloxacin resulted in stepwise increases in the MIC, with a mean proportional increase of 10. MICs were significantly lower in an iron-limited chemically defined medium than in Iso-Sensitest broth. The mucoid phenotype was maintained in chemically defined medium. Acquired resistance was retained either partially or completely in 85% of the isolates following 10 transfers in drug-free media. In cases in which susceptibility was regained, an increase in the MIC was observed on one further exposure to ciprofloxacin.

Full text

PDF
2649

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown M. R., Williams P. Influence of substrate limitation and growth phase on sensitivity to antimicrobial agents. J Antimicrob Chemother. 1985 Jan;15 (Suppl A):7–14. doi: 10.1093/jac/15.suppl_a.7. [DOI] [PubMed] [Google Scholar]
  2. Chamberland S., Malouin F., Rabin H. R., Schollaardt T., Parr T. R., Jr, Bryan L. E. Persistence of Pseudomonas aeruginosa during ciprofloxacin therapy of a cystic fibrosis patient: transient resistance to quinolones and protein F-deficiency. J Antimicrob Chemother. 1990 Jun;25(6):995–1010. doi: 10.1093/jac/25.6.995. [DOI] [PubMed] [Google Scholar]
  3. Eudy W. W., Burrous S. E. Generation times of Proteus mirabilis and Escherichia coli in experimental infections. Chemotherapy. 1973;19(3):161–170. doi: 10.1159/000221451. [DOI] [PubMed] [Google Scholar]
  4. Goldfarb J., Stern R. C., Reed M. D., Yamashita T. S., Myers C. M., Blumer J. L. Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. Am J Med. 1987 Apr 27;82(4A):174–179. [PubMed] [Google Scholar]
  5. Johanson W. G., Jr, Higuchi J. H., Chaudhuri T. R., Woods D. E. Bacterial adherence to epithelial cells in bacillary colonization of the respiratory tract. Am Rev Respir Dis. 1980 Jan;121(1):55–63. doi: 10.1164/arrd.1980.121.1.55. [DOI] [PubMed] [Google Scholar]
  6. Limb D. I., Dabbs D. J., Spencer R. C. In-vitro selection of bacteria resistant to the 4-quinolone agents. J Antimicrob Chemother. 1987 Jan;19(1):65–71. doi: 10.1093/jac/19.1.65. [DOI] [PubMed] [Google Scholar]
  7. Raeburn J. A., Govan J. R., McCrae W. M., Greening A. P., Collier P. S., Hodson M. E., Goodchild M. C. Ciprofloxacin therapy in cystic fibrosis. J Antimicrob Chemother. 1987 Sep;20(3):295–296. doi: 10.1093/jac/20.3.295. [DOI] [PubMed] [Google Scholar]
  8. Reeves D. S., Bywater M. J., Holt H. A., White L. O. In-vitro studies with ciprofloxacin, a new 4-quinolone compound. J Antimicrob Chemother. 1984 Apr;13(4):333–346. doi: 10.1093/jac/13.4.333. [DOI] [PubMed] [Google Scholar]
  9. Rådberg G., Nilsson L. E., Svensson S. Development of quinolone-imipenem cross resistance in Pseudomonas aeruginosa during exposure to ciprofloxacin. Antimicrob Agents Chemother. 1990 Nov;34(11):2142–2147. doi: 10.1128/aac.34.11.2142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Scully B. E., Neu H. C., Parry M. F., Mandell W. Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa. Lancet. 1986 Apr 12;1(8485):819–822. doi: 10.1016/s0140-6736(86)90937-2. [DOI] [PubMed] [Google Scholar]
  11. Shalit I., Stutman H. R., Marks M. I., Chartrand S. A., Hilman B. C. Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. Am J Med. 1987 Apr 27;82(4A):189–195. [PubMed] [Google Scholar]
  12. Steen H. J., Scott E. M., Stevenson M. I., Black A. E., Redmond A. O., Collier P. S. Clinical and pharmacokinetic aspects of ciprofloxacin in the treatment of acute exacerbations of pseudomonas infection in cystic fibrosis patients. J Antimicrob Chemother. 1989 Nov;24(5):787–795. doi: 10.1093/jac/24.5.787. [DOI] [PubMed] [Google Scholar]
  13. Tenney J. H., Maack R. W., Chippendale G. R. Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar. Antimicrob Agents Chemother. 1983 Jan;23(1):188–189. doi: 10.1128/aac.23.1.188. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES